The Pet Calming Supplements Category's $2 Billion Gap You Can Close Right Now

Your best customer wrote a review that said her dog "seems so much calmer since starting the chews." She meant it. She may even be right. But if you asked her to distinguish between the effect of your product and the fact that her neighbor stopped setting off fireworks in September, she couldn't. And neither can you.

That is the structural problem underneath the calming supplement category. Not the formulations. Not the ingredients. The fact that the entire segment, from the $12 bag at PetSmart to the high-end veterinary line, runs on the same evidence: owner perception. And owner perception, however sincere, is not a signal you can build retention on. It is the reason a customer buys twice and then quietly disappears when the next stressful period does not quite confirm what the last one suggested.

The category needs a number. A reading from the dog, not from the owner. One that exists before supplementation begins, continues throughout, and shows whether the animal's physiology actually shifted.

That number is heart rate variability. And collecting it has been, until now, impractical outside a clinical setting.

The measurement gap calming brands cannot close on their own

Most supplement companies track repurchase rate and lean on testimonials. The more disciplined ones run structured post-purchase surveys. A few fund clinical studies. Each approach has a ceiling that no amount of operational improvement will raise.

Testimonials capture the customers who felt a difference strongly enough to say so. They tell you nothing about the customers who felt nothing and stopped reordering without complaint. Surveys are subject to recall bias and to the well-documented tendency of owners who invested in a product to report improvement regardless of outcome. Clinical trials produce regulatory-grade claims but are expensive, slow to execute, and designed for controlled conditions that bear little resemblance to a household where the stressor is a new baby, a construction project next door, or a dog who has never liked Tuesdays.

None of these approaches measure the dog. They measure the owner's interpretation of the dog at a single point in time. And that interpretation is unreliable not because owners are careless, but because anxiety in dogs is episodic and variable in ways that make before-and-after comparisons almost impossible without instrumentation. A dog who was reactive during thunderstorm season in October may be noticeably calmer by December for reasons entirely unrelated to the supplement started in November. Without a physiological baseline on the individual animal, established before the supplement period begins and tracked continuously through it, there is nothing to measure against.

What HRV reveals that observation cannot

Heart rate variability is the variation in time between consecutive heartbeats. In dogs, as in humans, higher HRV during rest reflects parasympathetic dominance: the autonomic nervous system is not under load. Suppressed HRV reflects sympathetic activation, the physiological state that underlies anxiety, fear, and sustained stress.

The link between HRV and autonomic state is well-established in veterinary cardiology. Researchers have used HRV to measure canine stress responses to noise, separation, novel environments, and kenneling. It is not a new metric. What has been missing is the ability to collect it continuously, passively, in the home environment, across the specific stress events that actually drive a pet owner to reach for a calming product.

A single HRV reading taken at the vet tells you what the dog's nervous system was doing during a clinic visit, which is almost always stressful regardless of the dog's baseline temperament. A week of nightly readings, taken while the dog sleeps in its own bed in its own house, tells you something entirely different: where that individual animal's resting autonomic tone actually sits when nothing unusual is happening. That is the baseline. When HRV drops below it during a known stressor, that drop is quantified against the dog's own normal. And when HRV trends back toward baseline after two weeks on a calming supplement, the owner is not reporting a feeling. They are looking at a line, from their dog, moving in the right direction.

The PHH-23: continuous HRV without a wearable

The PHH-23 is a sensor pad that sits beneath a dog's resting surface. A bed. A crate mat. The corner of a couch they have claimed as theirs. No harness. No chest strap. No clip-on device the dog works loose within an hour of being fitted.

It uses ballistocardiography (BCG) to read the mechanical forces each heartbeat produces through the surface the dog rests on. From that signal, it derives heart rate, heart rate variability, resting respiratory rate, and nocturnal movement pattern. Continuously. Passively. Across every rest and sleep period without any action from the owner after the initial setup.

Because the PHH-23 records across days and weeks rather than clinic snapshots or short wearable sessions, it produces something no other consumer device in the category generates: an individual autonomic baseline built from that specific dog's own physiology. Not a breed average. Not an age-adjusted population estimate. The actual resting profile of that animal, established across calm periods and stressed ones, refined over time as the data set deepens.

That baseline is what makes every downstream application possible. Without it, HRV is a number. With it, HRV is a deviation from normal that means something specific about a specific dog on a specific day.

Four integration models for supplement brands

The stress trigger

A supplement brand with an existing app integrates with PHH-23 data through an API layer. When a dog's HRV drops more than one standard deviation below their individual baseline across two or more consecutive rest periods, the app surfaces a recommendation. Not a weekly push notification timed to a marketing calendar. A prompt that appears on the day the data shows the dog's autonomic state has shifted, with the reading visible to the owner so they understand why the recommendation is appearing.

The owner sees the number. They see the context. The brand is not pushing a product. The data is flagging a need. That distinction changes conversion because it removes the thing that makes most supplement marketing feel like noise: the suspicion that the timing is arbitrary.

SKU routing by anxiety profile

Situational anxiety and chronic anxiety are physiologically different, and the PHH-23 data shows the difference clearly. A dog with noise phobia produces an acute HRV drop on the evening of a thunderstorm and returns to baseline within 24 to 48 hours. A dog with generalized anxiety shows a chronically suppressed baseline with no clear episodic trigger and minimal recovery between events.

Most calming brands sell into both profiles with the same product or leave the customer to self-select from a product page, which many do poorly. PHH-23 data gives the brand the pattern before the purchase. The acute episodic profile routes to the fast-acting situational formula. The persistently suppressed baseline routes to the daily maintenance SKU. That is not segmentation by breed or age. It is the first time a supplement brand can make a product recommendation based on what the individual dog's autonomic nervous system is actually doing.

Real-world efficacy data at scale

This is the integration that changes the category's evidence base. If a supplement brand's customer base includes several thousand dogs on PHH-23, and those dogs are also on a 30-day calming protocol, the brand accumulates a real-world dataset: pre- and post-supplementation HRV trends across a large, varied population. Not a controlled clinical trial with 40 dogs under laboratory observation. Continuous physiological data from real households, collected passively as a byproduct of normal product use.

Whether HRV trends toward baseline across the supplementation period, at population scale, is the efficacy signal the calming category has never been able to produce. This is trend data rather than clinical proof of efficacy in the regulatory sense, and it requires a data-sharing agreement between the supplement brand and PuresPet. But as a real-world evidence base for product development, brand positioning, and conversations with veterinary professionals, nothing in the segment comes close.

The vet bridge

When a dog's HRV remains suppressed after two weeks on a calming supplement, showing no movement toward baseline or a continued decline, the integration flags this and recommends a veterinary consultation. The HRV trend report can be formatted for the vet appointment, giving the clinician a continuous home-environment record rather than a single reading taken while the dog is already stressed by the clinic visit itself.

The supplement brand becomes the company that recognized when the supplement alone was not enough and helped the owner take the right next step. That is not a lost sale. That is the brand a customer tells every dog owner they know about. Trust built at the moment of honest limitation is worth more than a hundred five-star reviews.

How this compares to what you are probably already using

Activity trackers measure movement. A less active dog may be calmer. Or in pain. Or aging. Or it rained for a week. Movement correlates weakly with anxiety and strongly with too many other variables to serve as a reliable product signal.

Owner-completed behavioral scales, including validated instruments like the Canine Behavioral Assessment and Research Questionnaire (C-BARQ), capture structured owner observation. They require regular completion, they still reflect human perception rather than physiology, and they produce periodic snapshots rather than continuous data.

Wearable cardiac monitors can produce HRV data. They depend entirely on owner compliance. A chest harness worn conscientiously for three days and then abandoned when the dog refuses to settle in it gives you an incomplete fragment of a single week. Compliance failure is not a minor operational issue in pet health monitoring. It is the reason continuous, long-term HRV data from dogs in home environments has not been commercially available until the PHH-23 removed the compliance variable altogether. The dog does not know the device is there.

Does It Fit Your Brand?

If you sell calming supplements through subscription or repeat-purchase channels and your retention depends on owners continuing to believe the product works, this integration replaces belief with evidence.

It fits best alongside an existing app or connected product experience, because HRV data is most actionable when it surfaces through a channel the owner already checks. A brand with no digital touchpoint between purchases will need to build one for this data to reach the customer where it matters.

If your model is single-unit retail and the goal is acquisition volume rather than lifetime value, this is not the right fit. The commercial advantage compounds across stress cycles and seasons. It is built for the brand that wants a customer who renews because they have seen what happened, not because they received a timely coupon.

What Your Customers See

Every calming supplement on the market makes a version of the same promise. Reduces stress. Supports calm behavior. Promotes relaxation. It is the same language, spoken in different ways. But there is no evidence behind it. The evidence rests on pet parents’ perception.

The first brand that shows a customer their own dog's HRV trending back toward baseline after two weeks consuming their product is not making a false promise. They are closing a loop. The difference between that experience and everything else on the market is not a competitive advantage. It is a category of one.